{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T18:19:57Z","timestamp":1774117197402,"version":"3.50.1"},"reference-count":148,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T00:00:00Z","timestamp":1595548800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["PTDC\/MED-QUI\/30591\/2017"],"award-info":[{"award-number":["PTDC\/MED-QUI\/30591\/2017"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["SAICT-PAC\/0019\/2015"],"award-info":[{"award-number":["SAICT-PAC\/0019\/2015"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["PhD grant PD\/BD\/135291\/2017"],"award-info":[{"award-number":["PhD grant PD\/BD\/135291\/2017"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Multidrug resistance (MDR) in cancer is one of the main limitations for chemotherapy success. Numerous mechanisms are behind the MDR phenomenon wherein the overexpression of the ATP-binding cassette (ABC) transporter proteins P-glycoprotein (P-gp), breast cancer resistance protein (BCRP) and multidrug resistance protein 1 (MRP1) is highlighted as a prime factor. Natural product-derived compounds are being addressed as promising ABC transporter modulators to tackle MDR. Flavonoids and terpenoids have been extensively explored in this field as mono or dual modulators of these efflux pumps. Nitrogen-bearing moieties on these scaffolds were proved to influence the modulation of ABC transporters efflux function. This review highlights the potential of semisynthetic nitrogen-containing flavonoid and terpenoid derivatives as candidates for the design of effective MDR reversers. A brief introduction concerning the major role of efflux pumps in multidrug resistance, the potential of natural product-derived compounds in MDR reversal, namely natural flavonoid and terpenoids, and the effect of the introduction of nitrogen-containing groups are provided. The main modifications that have been performed during last few years to generate flavonoid and terpenoid derivatives, bearing nitrogen moieties, such as aliphatic, aromatic and heterocycle amine, amide, and related functional groups, as well as their P-gp, MRP1 and BCRP inhibitory activities are reviewed and discussed.<\/jats:p>","DOI":"10.3390\/molecules25153364","type":"journal-article","created":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T09:19:27Z","timestamp":1595582367000},"page":"3364","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":64,"title":["Overcoming Multidrug Resistance: Flavonoid and Terpenoid Nitrogen-Containing Derivatives as ABC Transporter Modulators"],"prefix":"10.3390","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3137-5329","authenticated-orcid":false,"given":"Bruno","family":"M. F. Gon\u00e7alves","sequence":"first","affiliation":[{"name":"Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, 1649-003 Lisboa, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8270-4276","authenticated-orcid":false,"given":"David","family":"S. P. Cardoso","sequence":"additional","affiliation":[{"name":"Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, 1649-003 Lisboa, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8742-1486","authenticated-orcid":false,"given":"Maria-Jos\u00e9","family":"U. Ferreira","sequence":"additional","affiliation":[{"name":"Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, 1649-003 Lisboa, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2020,7,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.ejca.2018.07.005","article-title":"Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018","volume":"103","author":"Ferlay","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1146\/annurev-pharmtox-010715-103111","article-title":"Toward a better understanding of the complexity of cancer drug resistance","volume":"56","author":"Gottesman","year":"2016","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_3","first-page":"47","article-title":"Chapter 4 mechanisms of multidrug resistance in cancer","volume":"Volume 596","author":"Zhou","year":"2009","journal-title":"Multi-Drug Resistance in Cancer. Methods in Molecular Biology (Methods and Protocols)"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Bukowski, K., Kciuk, M., and Kontek, R. (2020). Mechanisms of multidrug resistance in cancer chemotherapy. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21093233"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Wang, X., Zhang, H., and Chen, X. (2019). Drug resistance and combating drug resistance in cancer. Cancer Drug Resist.","DOI":"10.20517\/cdr.2019.10"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Alexa-Stratulat, T., Pe\u0161i\u0107, M., Ga\u0161parovi\u0107, A.\u010c., Trougakos, I.P., and Riganti, C. (2019). What sustains the multidrug resistance phenotype beyond ABC efflux transporters? Looking beyond the tip of the iceberg. Drug Resist. Updat., 46.","DOI":"10.1016\/j.drup.2019.100643"},{"key":"ref_7","first-page":"1","article-title":"The role of eukaryotic and prokaryotic ABC transporter family in failure of chemotherapy","volume":"7","author":"Saleh","year":"2017","journal-title":"Front. Pharmacol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.taap.2004.10.012","article-title":"Multidrug resistance proteins: Role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense","volume":"204","author":"Leslie","year":"2005","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/s41568-018-0005-8","article-title":"Revisiting the role of ABC transporters in multidrug-resistant cancer","volume":"18","author":"Robey","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2165\/00003088-200342010-00003","article-title":"Role of P-Glycoprotein in pharmacokinetics","volume":"42","author":"Lin","year":"2003","journal-title":"Clin. Pharmacokinet."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1146\/annurev.biochem.71.102301.093055","article-title":"Mammalian ABC transporters in health and disease","volume":"71","author":"Borst","year":"2002","journal-title":"Annu. Rev. Biochem."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/nrd4461","article-title":"What do drug transporters really do?","volume":"14","author":"Nigam","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.canlet.2015.10.010","article-title":"Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade","volume":"370","author":"Chen","year":"2016","journal-title":"Cancer Lett."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/nsmb.3216","article-title":"Mechanistic diversity in ATP-binding cassette (ABC) transporters","volume":"23","author":"Locher","year":"2016","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/wcms.1196","article-title":"Reversing cancer multidrug resistance: Insights into the efflux by ABC transports from in silico studies","volume":"5","author":"Ferreira","year":"2015","journal-title":"Wiley Interdiscip. Rev. Comput. Mol. Sci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.bbamem.2017.10.028","article-title":"Comparison of mechanistic transport cycle models of ABC exporters","volume":"1860","author":"Hellmich","year":"2018","journal-title":"Biochim. Biophys. Acta-Biomembr."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2014.11.013","article-title":"Modulation of P-glycoprotein efflux pump: Induction and activation as a therapeutic strategy","volume":"149","author":"Silva","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1080\/00498250701867889","article-title":"Structure, Function and Regulation of P-Glycoprotein and Its Clinical Relevance in Drug Disposition","volume":"38","author":"Zhou","year":"2008","journal-title":"Xenobiotica."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0928-0987(00)00177-9","article-title":"Structure-activity relationship of P-glycoprotein substrates and modifiers","volume":"12","author":"Seelig","year":"2000","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1074\/jbc.M116.755884","article-title":"Structures of the multidrug transporter P-glycoprotein reveal asymmetric ATP binding and the mechanism of polyspecificity","volume":"292","author":"Esser","year":"2017","journal-title":"J. Biol. Chem."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.cell.2017.01.041","article-title":"Structural basis of substrate recognition by the multidrug resistance protein MRP1","volume":"168","author":"Johnson","year":"2017","journal-title":"Cell"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nature22345","article-title":"Structure of the human multidrug transporter ABCG2","volume":"546","author":"Taylor","year":"2017","journal-title":"Nature"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/s41586-018-0680-3","article-title":"Cryo-EM structures of a human ABCG2 mutant trapped in ATP-bound and substrate-bound states","volume":"563","author":"Manolaridis","year":"2018","journal-title":"Nature"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1126\/science.1360704","article-title":"Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line","volume":"258","author":"Cole","year":"1992","journal-title":"Science"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"15665","DOI":"10.1073\/pnas.95.26.15665","article-title":"A multidrug resistance transporter from human MCF-7 breast cancer cells","volume":"95","author":"Doyle","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_26","first-page":"5337","article-title":"A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance","volume":"58","author":"Allikmets","year":"1998","journal-title":"Cancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Ferreira, R.J., Bonito, C.A., Cordeiro, M.N.D.S., Ferreira, M.J.U., and Dos Santos, D.J.V.A. (2017). Structure-function relationships in ABCG2: Insights from molecular dynamics simulations and molecular docking studies. Sci. Rep., 7.","DOI":"10.1038\/s41598-017-15452-z"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.addr.2008.11.003","article-title":"ABCG2: A perspective","volume":"61","author":"Robey","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1126\/science.aar7389","article-title":"Molecular structure of human P-glycoprotein in the ATP-bound, outward-facing conformation","volume":"7389","author":"Kim","year":"2018","journal-title":"Science"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Orlando, B.J., and Liao, M. (2020). ABCG2 transports anticancer drugs via a closed-to-open switch. Nat. Commun., 11.","DOI":"10.1038\/s41467-020-16155-2"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.4155\/fmc-2019-0185","article-title":"Multi-target ABC transporter modulators: What next and where to go?","volume":"11","author":"Stefan","year":"2019","journal-title":"Future Med. Chem."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"6","DOI":"10.20517\/cdr.2018.02","article-title":"How to overcome ATP-binding cassette drug efflux transporter-mediated drug resistance?","volume":"1","author":"Jaramillo","year":"2018","journal-title":"Cancer Drug Resist."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.2174\/092986712800167392","article-title":"Three decades of P-gp inhibitors: Skimming through several generations and scaffolds","volume":"19","author":"Palmeira","year":"2012","journal-title":"Curr. Med. Chem."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1200\/JCO.1995.13.8.1985","article-title":"Phase I and pharmacokinetic study of the multidrug resistance modulator dexverapamil with EPOCH chemotherapy","volume":"13","author":"Wilson","year":"1995","journal-title":"J. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1200\/JCO.1998.16.9.2964","article-title":"Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP","volume":"16","author":"Rowinsky","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/ijc.10792","article-title":"Modulation of P-glycoprotein but not MRP1- or BCRP-mediated drug resistance by LY335979","volume":"103","author":"Shepard","year":"2003","journal-title":"Int. J. Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Tang, R., Faussat, A.M., Perrot, J.Y., Marjanovic, Z., Cohen, S., Storme, T., Morjani, H., Legrand, O., and Marie, J.P. (2008). Zosuquidar restores drug sensitivity in P-glycoprotein expressing acute myeloid leukemia (AML). BMC Cancer, 8.","DOI":"10.1186\/1471-2407-8-51"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1007\/s00280-015-2845-1","article-title":"Pharmacokinetic and pharmacodynamic study of tariquidar (XR9576), a P-glycoprotein inhibitor, in combination with doxorubicin, vinorelbine, or docetaxel in children and adolescents with refractory solid tumors","volume":"76","author":"Fox","year":"2015","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"406","DOI":"10.3109\/03602532.2015.1105253","article-title":"MRP1 and its role in anticancer drug resistance","volume":"47","author":"Lu","year":"2015","journal-title":"Drug Metab. Rev."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1200\/JCO.2006.08.1646","article-title":"Dofequidar fumarate (MS-209) in combination with cyclophosphamide, doxorubicin, and fluorouracil for patients with advanced or recurrent breast cancer","volume":"25","author":"Saeki","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_41","first-page":"79","article-title":"A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer","volume":"59","author":"Ballot","year":"2007","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/med.21510","article-title":"Small-molecule inhibitors of multidrug resistance-associated protein 1 and related processes: A historic approach and recent advances","volume":"39","author":"Stefan","year":"2019","journal-title":"Med. Res. Rev."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/00001813-200603000-00001","article-title":"Inhibitors of cancer cell multidrug resistance mediated by breast cancer resistance protein (BCRP\/ABCG2)","volume":"17","author":"Pozza","year":"2006","journal-title":"Anticancer Drugs"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Toyoda, Y., Takada, T., and Suzuki, H. (2019). Inhibitors of human ABCG2: From technical Background to recent updates with clinical implications. Front. Pharmacol., 10.","DOI":"10.3389\/fphar.2019.00208"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1021\/cn100078a","article-title":"The \u201cspecific\u201d P-glycoprotein inhibitor tariquidar is also a substrate and an inhibitor for Breast Cancer Resistance Protein (BCRP\/ABCG2)","volume":"2","author":"Kannan","year":"2011","journal-title":"ACS Chem. Neurosci."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1158\/0008-5472.CAN-03-3298","article-title":"Pheophorbide a is a specific probe for ABCG2 function and inhibition","volume":"64","author":"Robey","year":"2004","journal-title":"Cancer Res."},{"key":"ref_47","first-page":"4237","article-title":"The mouse Bcrp1\/Mxr\/Abcp gene: Amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin","volume":"59","author":"Allen","year":"1999","journal-title":"Cancer Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ejmech.2017.07.062","article-title":"Overcoming ABC transporter-mediated multidrug resistance: The dual role of tyrosine kinase inhibitors as multitargeting agents","volume":"142","author":"Beretta","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1158\/1535-7163.MCT-10-0197","article-title":"A synergistic interaction between lapatinib and chemotherapy agents in a panel of cell lines is due to the inhibition of the efflux pump BCRP","volume":"9","author":"Perry","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/cmdc.201100543","article-title":"Tyrosine kinase inhibitors influence ABCG2 expression in EGFR-positive MDCK BCRP cells via the PI3K\/Akt signaling pathway","volume":"7","author":"Pick","year":"2012","journal-title":"ChemMedChem"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"867","DOI":"10.3109\/14756366.2016.1149476","article-title":"Advances in plant-based inhibitors of P-glycoprotein","volume":"31","author":"Yu","year":"2016","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1042\/bse0500209","article-title":"The controversial role of ABC transporters in clinical oncology","volume":"50","author":"Tamaki","year":"2011","journal-title":"Essays Biochem."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1002\/cncr.21666","article-title":"Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar\/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): A trial of the Eastern Cooperative Oncology Group","volume":"106","author":"Friedenberg","year":"2006","journal-title":"Cancer"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/cncr.22492","article-title":"A phase II study of the safety and efficacy of the multidrug resistance inhibitor VX-710 combined with doxorubicin and vincristine in patients with recurrent small cell lung cancer","volume":"109","author":"Gandhi","year":"2007","journal-title":"Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1158\/1078-0432.CCR-10-1725","article-title":"A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer","volume":"17","author":"Kelly","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"4077","DOI":"10.1182\/blood-2010-04-277269","article-title":"Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: A randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999","volume":"116","author":"Cripe","year":"2010","journal-title":"Blood"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1158\/1078-0432.CCR-06-2414","article-title":"A phase I, randomized, open-label, parallel-cohort, dose-finding study of elacridar (GF120918) and oral topotecan in cancer patients","volume":"13","author":"Kuppens","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_58","unstructured":"John Crown, M. (2020, April 08). Phase II Trial of the Multi-Drug Resistance Protein Modulating Agent Sulindac in Combination with Epirubicin in Patients with Advanced Melanoma, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00755976?term=sulindac+and+epirubicin&draw=2&rank=1."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"TPS11077","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS11077","article-title":"CBT-1 in combination with doxorubicin in patients with metastatic, unresectable sarcomas who previously progressed on doxorubicin","volume":"37","author":"Cote","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s00280-014-2385-0","article-title":"Phase I dosage finding and pharmacokinetic study of intravenous topotecan and oral erlotinib in adults with refractory solid tumors","volume":"73","author":"Stewart","year":"2014","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ygyno.2011.03.030","article-title":"Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory\/resistant ovarian and primary peritoneal carcinoma","volume":"122","author":"Weroha","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"605","DOI":"10.2174\/1871520615666150113103439","article-title":"Development of fourth generation abc inhibitors from natural products: A novel approach to overcome cancer multidrug resistance","volume":"15","author":"Karthikeyan","year":"2015","journal-title":"Anticancer Agents Med. Chem."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Ye, Q., Liu, K., Shen, Q., Li, Q., Hao, J., Han, F., and Jiang, R.W. (2019). Reversal of multidrug resistance in cancer by multi-functional flavonoids. Front. Oncol., 9.","DOI":"10.3389\/fonc.2019.00487"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ejmech.2019.05.027","article-title":"Natural products as multidrug resistance modulators in cancer","volume":"176","author":"Kumar","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.ejmech.2017.01.044","article-title":"Dregamine and tabernaemontanine derivatives as ABCB1 modulators on resistant cancer cells","volume":"128","author":"Paterna","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.bmc.2017.11.052","article-title":"Monoterpene indole alkaloid azine derivatives as MDR reversal agents","volume":"26","author":"Paterna","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ejphar.2008.10.025","article-title":"Effects of chemopreventive citrus phytochemicals on human P-glycoprotein and multidrug resistance protein 1","volume":"600","author":"Nabekura","year":"2008","journal-title":"Eur. J. Pharmacol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S0006-2952(96)00826-X","article-title":"Effect of quercetin in Hoechst 33342 transport by purified and reconstituted P-glycoprotein","volume":"53","author":"Shapiro","year":"1997","journal-title":"Biochem. Pharmacol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.3892\/mmr.2013.1742","article-title":"Icaritin reverses multidrug resistance of HepG2\/ADR human hepatoma cells via downregulation of MDR1 and P-glycoprotein expression","volume":"8","author":"Sun","year":"2013","journal-title":"Mol. Med. Rep."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1016\/j.bmc.2010.12.043","article-title":"Structure\u2013activity relationships of flavonoids as inhibitors of breast cancer resistance protein (BCRP)","volume":"19","author":"Pick","year":"2011","journal-title":"Bioorg. Med. Chem."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Wu, C.-P., Lusvarghi, S., Hsiao, S.-H., Liu, T.-C., Li, Y.-Q., Huang, Y.-H., Hung, T.-H., and Ambudkar, S.V. (2019). Licochalcone a selectively resensitizes ABCG2-overexpressing multidrug-resistant cancer cells to chemotherapeutic drugs. J. Nat. Prod.","DOI":"10.1021\/acs.jnatprod.9b01022"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.4155\/fmc.15.83","article-title":"Design of inhibitors of BCRP\/ABCG2","volume":"7","author":"Juvale","year":"2015","journal-title":"Future Med. Chem."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1124\/mol.59.5.1171","article-title":"Modulation of multidrug resistance protein 1 (MRP1\/ABCC1) transport and ATpase activities by interaction with dietary flavonoids","volume":"59","author":"Leslie","year":"2001","journal-title":"Mol. Pharmacol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"92","DOI":"10.18433\/J3BW2S","article-title":"Karanjin interferes with ABCB1, ABCC1, and ABCG2","volume":"17","author":"Michaelis","year":"2014","journal-title":"J. Pharm. Pharm. Sci."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"6942","DOI":"10.1016\/j.bmc.2009.08.020","article-title":"New potent P-glycoprotein modulators with the cucurbitane scaffold and their synergistic interaction with doxorubicin on resistant cancer cells","volume":"17","author":"Ramalhete","year":"2009","journal-title":"Bioorg. Med. Chem."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"3696","DOI":"10.1016\/j.bmc.2014.05.006","article-title":"Macrocyclic diterpenes resensitizing multidrug resistant phenotypes","volume":"22","author":"Reis","year":"2014","journal-title":"Bioorg. Med. Chem."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"5061","DOI":"10.1016\/j.bmc.2016.08.022","article-title":"Triterpenoids from momordica balsamina: Reversal of ABCB1-mediated multidrug resistance","volume":"24","author":"Ramalhete","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"M\u00f3nico, A., Ramalhete, C., Andr\u00e9, V., Spengler, G., Mulhovo, S., Duarte, M.T., and Ferreira, M.J.U. (2019). Cucurbalsaminones A\u2212C, rearranged triterpenoids with a 5\/6\/3\/6\/5-fused pentacyclic carbon skeleton from momordica balsamina, as multidrug resistance reversers. J. Nat. Prod., 2138\u20132143.","DOI":"10.1021\/acs.jnatprod.9b00019"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.phymed.2016.05.007","article-title":"Jatrophane diterpenes and cancer multidrug resistance\u2014ABCB1 efflux modulation and selective cell death induction","volume":"23","author":"Reis","year":"2016","journal-title":"Phytomedicine"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s11101-014-9342-8","article-title":"Euphorbia and Momordica metabolites for overcoming multidrug resistance","volume":"13","author":"Ferreira","year":"2014","journal-title":"Phytochem. Rev."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"6392","DOI":"10.1016\/j.bmc.2014.09.041","article-title":"Improving the MDR reversal activity of 6,17-epoxylathyrane diterpenes","volume":"22","author":"Vieira","year":"2014","journal-title":"Bioorg. Med. Chem."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1021\/acs.jnatprod.8b00326","article-title":"Terpenoids from euphorbia pedroi as multidrug-resistance reversers","volume":"81","author":"Ferreira","year":"2018","journal-title":"J. Nat. Prod."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"6757","DOI":"10.3390\/ijms13066757","article-title":"Effects of 3\u03b2-acethyl tormentic acid (3ATA) on ABCC proteins activity","volume":"13","author":"Oliveira","year":"2012","journal-title":"Int. J. Mol. Sci."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.ejmech.2019.05.053","article-title":"Design, synthesis and biological evaluation of chalcones as reversers of P-glycoprotein-mediated multidrug resistance","volume":"180","author":"Yin","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"ref_85","unstructured":"Prudhomme, M. (2009). Recent developments of P-gp inhibitors. Advances in Anticancer Agents in Medicinal Chemistry, Benthan E books."},{"key":"ref_86","first-page":"454","article-title":"Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells","volume":"4","author":"Zamora","year":"1988","journal-title":"Mol. Pharmacol."},{"key":"ref_87","first-page":"791","article-title":"The importance of a nitrogen atom in modulators of multidrug resistance","volume":"56","author":"Ecker","year":"1999","journal-title":"Mol. Pharmacol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1002\/cmdc.200700160","article-title":"Multispecificity of drug transporters: Probing inhibitor selectivity for the human drug efflux transporters ABCB1 and ABCG2","volume":"2","author":"Cramer","year":"2007","journal-title":"ChemMedChem"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Schwarz, T., Montanari, F., Cseke, A., Wlcek, K., Visvader, L., Palme, S., Chiba, P., Kuchler, K., Urban, E., and Ecker, G.F. (2016). Subtle structural differences trigger inhibitory activity of propafenone analogues at the two polyspecific ABC transporters: P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP). ChemMedChem, 1380\u20131394.","DOI":"10.1002\/cmdc.201500592"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"5449","DOI":"10.1021\/acs.jmedchem.6b00330","article-title":"Synthesis and biological evaluation of 4-Anilino-quinazolines and-quinolines as inhibitors of breast cancer resistance protein (ABCG2)","volume":"59","author":"Krapf","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"7952","DOI":"10.1021\/acs.jmedchem.8b01011","article-title":"2,4,6-Substituted quinazolines with extraordinary inhibitory potency toward ABCG2","volume":"61","author":"Krapf","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ejmech.2015.12.010","article-title":"Flavonoid derivatives as selective ABCC1 modulators: Synthesis and functional characterization","volume":"109","author":"Sun","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Panche, A.N., Diwan, A.D., and Chandra, S.R. (2016). Flavonoids: An overview. J. Nutr. Sci., 5.","DOI":"10.1017\/jns.2016.41"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1002\/elps.201600334","article-title":"Flavonoids biosynthesis in plants and its further analysis by capillary electrophoresis","volume":"38","author":"Singh","year":"2017","journal-title":"Electrophoresis"},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Dewick, P.M. (2009). Medicinal Natural Products\u2014A Biosynthetic Approach, John Wiley & Sons, Inc.. [3rd ed.].","DOI":"10.1002\/9780470742761"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00044-013-0612-6","article-title":"Impact of ABC transporters, glutathione conjugates in MDR and their modulation by flavonoids: An overview","volume":"23","author":"Gupta","year":"2014","journal-title":"Med. Chem. Res."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S0960-894X(00)00072-X","article-title":"Antitumor agents. Part 202: Novel 2\u2032-amino chalcones: Design, synthesis and biological evaluation","volume":"10","author":"Xia","year":"2000","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.bmc.2007.10.006","article-title":"Functionalized chalcones as selective inhibitors of P-glycoprotein and breast cancer resistance protein","volume":"16","author":"Liu","year":"2008","journal-title":"Bioorg. Med. Chem."},{"key":"ref_99","first-page":"609","article-title":"Quinoxaline-substituted chalcones as new inhibitors of breast cancer resistance protein ABCG2: Polyspecificity at B-ring position","volume":"8","author":"Winter","year":"2014","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ejmech.2016.03.067","article-title":"The combination of quinazoline and chalcone moieties leads to novel potent heterodimeric modulators of breast cancer resistance protein (BCRP\/ABCG2)","volume":"117","author":"Kraege","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1002\/cmdc.201600341","article-title":"Acryloylphenylcarboxamides: A new class of breast cancer resistance protein (ABCG2) modulators","volume":"11","author":"Kraege","year":"2016","journal-title":"ChemMedChem"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1002\/cmdc.201600455","article-title":"Optimization of acryloylphenylcarboxamides as inhibitors of ABCG2 and comparison with acryloylphenylcarboxylates","volume":"11","author":"Kraege","year":"2016","journal-title":"ChemMedChem"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ejmech.2018.12.019","article-title":"Novel chalcone and flavone derivatives as selective and dual inhibitors of the transport proteins ABCB1 and ABCG2","volume":"164","author":"Silbermann","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"725","DOI":"10.4155\/fmc-2017-0228","article-title":"Optimizing the flavanone core toward new selective nitrogen-containing modulators of ABC transporters","volume":"10","author":"Ferreira","year":"2018","journal-title":"Future Med. Chem."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1021\/jm981064b","article-title":"Flavonoid-related modulators of multidrug resistance: Synthesis, pharmacological activity, and structure-activity relationships","volume":"42","author":"Chapuis","year":"1999","journal-title":"J. Med. Chem."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/sj.leu.2400698","article-title":"Functional assay of multidrug resistant cells using JC-1, a carbocyanine fluorescent probe","volume":"11","author":"Perrot","year":"1997","journal-title":"Leukemia"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"4529","DOI":"10.1021\/acs.jmedchem.5b00085","article-title":"Potent and nontoxic chemosensitizer of P-glycoprotein-mediated multidrug resistance in cancer: Synthesis and evaluation of methylated epigallocatechin, gallocatechin, and dihydromyricetin derivatives","volume":"58","author":"Wong","year":"2015","journal-title":"J. Med. Chem."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Yan, C.S.W., Wong, I.L.K., Chan, K.-F., Kan, J.W.Y., Chong, T.C., Law, M.C., Zhao, Y., Chan, S.W., Chan, T.H., and Chow, L.M.C. (2015). A new class of safe, potent, and specific P-gp modulator: Flavonoid dimer FD18 reverses P-gp-mediated multidrug resistance in human breast xenograft in vivo. Mol. Pharm., 3507\u20133517.","DOI":"10.1021\/mp500770e"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"6742","DOI":"10.1021\/jm060593+","article-title":"Flavonoid dimers as bivalent modulators for P-glycoprotein-based multidrug resistance: Synthetic apigenin homodimers linked with defined-length poly(ethylene glycol) spacers increase drug retention and enhance chemosensitivity in resistant cancer cells","volume":"49","author":"Chan","year":"2006","journal-title":"J. Med. Chem."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1002\/cmdc.200800413","article-title":"Flavonoid dimers as bivalent modulators for P-glycoprotein-based multidrug resistance: Structure-activity relationships","volume":"4","author":"Chan","year":"2009","journal-title":"ChemMedChem"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1021\/jm201121b","article-title":"Amine linked flavonoid dimers as modulators for P-glycoprotein-based multidrug resistance: Structure-activity relationship and mechanism of modulation","volume":"55","author":"Chan","year":"2012","journal-title":"J. Med. Chem."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"9931","DOI":"10.1021\/acs.jmedchem.8b00834","article-title":"Discovery of novel flavonoid dimers to reverse multidrug resistance protein 1 (MRP1, ABCC1) mediated drug resistance in cancers using a high throughput platform with \u201cclick Chemistry\u201d","volume":"61","author":"Wong","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"8578","DOI":"10.1021\/acs.jmedchem.9b00963","article-title":"Triazole bridged flavonoid dimers as potent, nontoxic, and highly selective breast cancer resistance protein (BCRP\/ABCG2) inhibitors","volume":"62","author":"Zhu","year":"2019","journal-title":"J. Med. Chem."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.bmc.2017.11.016","article-title":"Design and synthesis of aminoester heterodimers containing flavone or chromone moieties as modulators of P-glycoprotein-based multidrug resistance (MDR)","volume":"26","author":"Dei","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Ay, M., Charli, A., Jin, H., Anantharam, V., Kanthasamy, A., and Kanthasamy, A.G. (2016). Quercetin. Nutraceuticals Effic. Saf. Toxic., 447\u2013452.","DOI":"10.1016\/B978-0-12-802147-7.00032-2"},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Shebeko, S.K., Zupanets, I.A., Popov, O.S., Tarasenko, O.O., and Shalamay, A.S. (2018). Chapter 27\u2014Effects of Quercetin and Its Combinations on Health. Polyphenols: Mechanisms of Action in Human Health and Disease, Elsevier Inc.. [2nd ed.].","DOI":"10.1016\/B978-0-12-813006-3.00027-1"},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Miltonprabu, S. (2019). Chapter 2.9\u2014Quercetin: A Flavonol with Versatile Therapeutic Applications and Its Interactions with Other Drugs. Nonvitamin and Nonmineral Nutritional Supplements, Elsevier Inc.","DOI":"10.1016\/B978-0-12-812491-8.00010-2"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"7216","DOI":"10.1021\/jm500290c","article-title":"Water-soluble and cleavable quercetin-amino acid conjugates as safe modulators for P-glycoprotein-based multidrug resistance","volume":"57","author":"Kim","year":"2014","journal-title":"J. Med. Chem."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1080\/10408399709527797","article-title":"The chemistry of tea flavonoids","volume":"37","author":"Balentine","year":"1997","journal-title":"Crit. Rev. Food Sci. Nutr."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"4957","DOI":"10.1021\/jf070323f","article-title":"Simultaneous analysis of catechins, gallic acid, strictinin, and purine alkaloids in green tea by using catechol as an internal standard","volume":"55","author":"Mizukami","year":"2007","journal-title":"J. Agric. Food Chem."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/nrc2129","article-title":"Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer","volume":"7","author":"Liby","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Sawai, S., and Saito, K. (2011). Triterpenoid biosynthesis and engineering in plants. Front. Plant Sci., 2.","DOI":"10.3389\/fpls.2011.00025"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1744-7909.2007.00395.x","article-title":"Plant terpenoids: Biosynthesis and ecological functions","volume":"49","author":"Cheng","year":"2007","journal-title":"J. Integr. Plant Biol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.drudis.2013.07.018","article-title":"Triterpenoids as reversal agents for anticancer drug resistance treatment","volume":"19","author":"Yan","year":"2014","journal-title":"Drug Discov. Today"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1021\/acs.jnatprod.5b00370","article-title":"Epoxylathyrol derivatives: Modulation of ABCB1-mediated multidrug resistance in human colon adenocarcinoma and mouse T-lymphoma cells","volume":"78","author":"Matos","year":"2015","journal-title":"J. Nat. Prod."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1021\/acs.jnatprod.6b01084","article-title":"Exploring jolkinol D derivatives to overcome multidrug resistance in cancer","volume":"80","author":"Reis","year":"2017","journal-title":"J. Nat. Prod."},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Reis, M.A., Matos, A.M., Duarte, N., Ahmed, O.B., Ferreira, R.J., Lage, H., and Ferreira, M.J.U. (2020). Epoxylathyrane derivatives as MDR-selective compounds for disabling multidrug resistance in cancer. Front. Pharmacol., 11.","DOI":"10.3389\/fphar.2020.00599"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"4808","DOI":"10.1021\/jm070290v","article-title":"Biological evaluation, structure-activity relationships, and three-dimensional quantitative structure-activity relationship studies of dihydro-\u03b2-agarofuran sesquiterpenes as modulators of P-glycoprotein-dependent multidrug resistance","volume":"50","author":"Reyes","year":"2007","journal-title":"J. Med. Chem."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1021\/acs.jmedchem.5b01429","article-title":"Optimization by molecular fine tuning of dihydro-\u03b2-agarofuran sesquiterpenoids as reversers of P-glycoprotein-mediated multidrug resistance","volume":"59","author":"Callies","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Chou","year":"1984","journal-title":"Adv. Enzym. Regul."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1021\/mp300249s","article-title":"BBA, a derivative of 23-hydroxybetulinic acid, potently reverses ABCB1-mediated drug resistance in vitro and in vivo","volume":"9","author":"Zhang","year":"2012","journal-title":"Mol. Pharm."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/CAD.0b013e32835fcc77","article-title":"Bipiperidinyl derivatives of 23-hydroxybetulinic acid reverse resistance of HepG2\/ADM and MCF-7\/ADR cells","volume":"24","author":"Zhang","year":"2013","journal-title":"Anticancer Drugs"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.canlet.2006.06.008","article-title":"Oleanolic acid inhibits the activity of the multidrug resistance protein ABCC1 (MRP1) but not of the ABCB1 (P-glycoprotein): Possible use in cancer chemotherapy","volume":"248","author":"Braga","year":"2007","journal-title":"Cancer Lett."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jnutbio.2013.12.003","article-title":"Oleanolic and maslinic acid sensitize soft tissue sarcoma cells to doxorubicin by inhibiting the multidrug resistance protein MRP-1, but not P-glycoprotein","volume":"25","author":"Villar","year":"2014","journal-title":"J. Nutr. Biochem."},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Paszel-Jaworska, A., Rubi\u015b, B., Bednarczyk-Cwynar, B., Zaprutko, L., and Rybczy\u0144ska, M. (2015). Proapoptotic activity and ABCC1-related multidrug resistance reduction ability of semisynthetic oleanolic acid derivatives DIOXOL and HIMOXOL in human acute promyelocytic leukemia cells. Chem. Biol. Interact., 242.","DOI":"10.1016\/j.cbi.2015.07.011"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1021\/jm5019302","article-title":"Synthesis of CDDO-amino acid-nitric oxide donor trihybrids as potential antitumor agents against both drug-sensitive and drug-resistant colon cancer","volume":"58","author":"Ai","year":"2015","journal-title":"J. Med. Chem."},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Zhu, B., Ren, C., Du, K., Zhu, H., Ai, Y., Kang, F., Luo, Y., Liu, W., Wang, L., and Yang, X. (2019). Olean-28,13b-olide 2 plays a role in cisplatin-mediated apoptosis and reverses cisplatin resistance in human lung cancer through multiple signaling pathways. Biochem. Pharmacol., 170.","DOI":"10.1016\/j.bcp.2019.113642"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.taap.2018.01.015","article-title":"H6, a novel hederagenin derivative, reverses multidrug resistance in vitro and in vivo","volume":"341","author":"Yang","year":"2018","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.ejmech.2018.10.033","article-title":"Synthesis and biological evaluation of novel H6 analogues as drug resistance reversal agents","volume":"161","author":"Wang","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"24188","DOI":"10.1039\/C8RA03666G","article-title":"Current knowledge and development of hederagenin as a promising medicinal agent: A comprehensive review","volume":"8","author":"Zeng","year":"2018","journal-title":"RSC Adv."},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Kim, E.H., Baek, S., Shin, D., Lee, J., and Roh, J.L. (2017). Hederagenin induces apoptosis in cisplatin-resistant head and neck cancer cells by inhibiting the Nrf2-ARE antioxidant pathway. Oxid. Med. Cell. Longev., 2017.","DOI":"10.1155\/2017\/5498908"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ejmech.2017.09.016","article-title":"Design, synthesis and biological evaluation of novel \u03b1-hederagenin derivatives with anticancer activity","volume":"141","author":"Liu","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1055\/s-0029-1185477","article-title":"20S-protopanaxadiol inhibits P-glycoprotein in multidrug resistant cancer cells","volume":"75","author":"Zhao","year":"2009","journal-title":"Planta Med."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"4279","DOI":"10.1016\/j.bmc.2013.04.067","article-title":"20(S)-Protopanaxadiol (PPD) analogues chemosensitize multidrug-resistant cancer cells to clinical anticancer drugs","volume":"21","author":"Liu","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"9388","DOI":"10.18632\/oncotarget.7011","article-title":"A 20(S)-protopanoxadiol derivative overcomes multi-drug resistance by antagonizing ATP-binding cassette subfamily B member 1 transporter function","volume":"7","author":"Chen","year":"2016","journal-title":"Oncotarget"},{"key":"ref_146","first-page":"5891","article-title":"A 20(S)-protopanaxadiol derivative PPD12 reverse ABCB1-mediated multidrug resistance with oral bioavailability and low toxicity","volume":"16","author":"Wei","year":"2018","journal-title":"Oncol. Lett."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"24277","DOI":"10.18632\/oncotarget.4493","article-title":"Semi-synthetic ocotillol analogues as selective ABCB1-mediated drug resistance reversal agents","volume":"6","author":"Zhang","year":"2015","journal-title":"Oncotarget"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ejmech.2018.10.038","article-title":"Design, synthesis, and discovery of ocotillol-type amide derivatives as orally available modulators of P-glycoprotein-mediated multidrug resistance","volume":"161","author":"Ren","year":"2019","journal-title":"Eur. J. Med. Chem."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/25\/15\/3364\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:51:31Z","timestamp":1760176291000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/25\/15\/3364"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,24]]},"references-count":148,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2020,8]]}},"alternative-id":["molecules25153364"],"URL":"https:\/\/doi.org\/10.3390\/molecules25153364","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,24]]}}}